Cargando…
60. Creation and Comparison of a Machine Learning Decision Tree and Traditional Risk Score to Predict Ceftriaxone Resistance in Cancer Patients with E. coli Bacteremia
BACKGROUND: There are several clinical tools that have been developed to predict the likelihood of extended-spectrum β-lactamase producing Enterobacterales; however, the creation of these tools included few patients with cancer or otherwise immunosuppressed. The objectives of this retrospective coho...
Autores principales: | Moc, Courtney, Shropshire, William, McDaneld, Patrick, Shelburne, Samuel A, Aitken, Samuel L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643720/ http://dx.doi.org/10.1093/ofid/ofab466.060 |
Ejemplares similares
-
305. Prevalence of Ceftriaxone Susceptible, Piperacillin-tazobactam Non-susceptible Escherichia coli Bacteremia in Patients with Hematologic Malignancy
por: Spitznogle, Sarah L, et al.
Publicado: (2020) -
1055. Epidemiology and Mechanisms of Carbapenem Resistance in Recurrent Extended-Spectrum β-Lactamase- Producing Enterobacteriaceae Bacteremia
por: Aitken, Samuel L, et al.
Publicado: (2018) -
2246. Improved Outcomes for Cancer Patients Treated With Ceftazidime–Avibactam vs. Polymyxin-Containing Regimens for Carbapenem-Resistant Enterobacteriaceae Bacteremia
por: Borjan, Jovan, et al.
Publicado: (2019) -
Temporal dynamics of genetically heterogeneous extended-spectrum cephalosporin-resistant Escherichia coli bloodstream infections
por: Shropshire, William C., et al.
Publicado: (2023) -
605. Identification of a Novel CMY-Variant Enzyme in a Clinical Escherichia coli Strain with Treatment-Emergent Ceftazidime–Avibactam Resistance
por: Aitken, Samuel L, et al.
Publicado: (2019)